In a prespecified exploratory analysis of the phase 3 NAVIGATOR clinical trial, a greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab than placebo. The study abstract was presented at the American Thoracic Society’s (ATS) International Conference 2022, held May 13-18 in San Francisco by Njira Lugogo, MD. Dr Lugogo is an associate professor of internal medicine and director of the Asthma Program in the Division of Pulmonary and Critical Care Medicine at the University of Michigan.
In the video below, Dr Lugogo sat down with Patient Care Online to discuss the impetus for the analysis, the overall results, and key takeaways for primary care clinicians.
Reference: Lugogo NL, Ambrose CS, Colice G, et al. Clinical responses to treatment with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study. Abstract presented at: The ATS International Conference; May 13-18, 2022; San Francisco, CA. Abstract available at: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A3419